Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Aug;93(8):3124-7.
doi: 10.1210/jc.2008-0287. Epub 2008 May 27.

Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome

Collaborators, Affiliations
Multicenter Study

Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome

Nicholas A Cataldo et al. J Clin Endocrinol Metab. 2008 Aug.

Abstract

Context: When used for ovulation induction, higher doses of clomiphene may lead to antiestrogenic side effects that reduce fecundity. It has been suggested that metformin in combination with clomiphene can restore ovulation to some clomiphene-resistant anovulators with polycystic ovary syndrome (PCOS).

Objective: Our objective was to determine if cotreatment with extended-release metformin (metformin XR) can lower the threshold dose of clomiphene needed to induce ovulation in women with PCOS.

Design: A secondary analysis of data from the National Institute of Child Health and Human Development Cooperative Multicenter Reproductive Medicine Network prospective, double-blind, placebo-controlled multicenter clinical trial, Pregnancy in Polycystic Ovary Syndrome, was performed.

Setting: Study volunteers at multiple academic medical centers were included.

Participants: Women with PCOS and elevated serum testosterone who were randomized to clomiphene alone or with metformin (n = 209 in each group) were included in the study.

Interventions: Clomiphene citrate, 50 mg daily for 5 d, was increased to 100 and 150 mg in subsequent cycles if ovulation was not achieved; half also received metformin XR, 1000 mg twice daily. Treatment was for up to 30 wk or six cycles, or until first pregnancy.

Main outcome measures: Ovulation was confirmed by a serum progesterone more than or equal to 5 ng/ml, drawn prospectively every 1-2 wk.

Results: The overall prevalence of at least one ovulation after clomiphene was 75 and 83% (P = 0.04) for the clomiphene-only and clomiphene plus metformin groups, respectively. Using available data from 314 ovulators, the frequency distribution of the lowest clomiphene dose (50, 100, or 150 mg daily) resulting in ovulation was indistinguishable between the two treatment groups.

Conclusion: Metformin XR does not reduce the lowest dose of clomiphene that induces ovulation in women with PCOS.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 377–384
    1. Ehrmann DA 2005 Polycystic ovary syndrome. N Engl J Med 352:1223–1236 - PubMed
    1. Homburg R 2005 Clomiphene citrate–end of an era? A mini-review. Hum Reprod 20:2043–2051 - PubMed
    1. Lord JM, Flight IH, Norman RJ 2003 Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951–953 - PMC - PubMed
    1. Mor E, Zograbyan A, Saadat P, Bayrak A, Tourgeman DE, Zhang C, Stanczyk FZ, Paulson RJ 2004 The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. Am J Obstet Gynecol 190:1654–1660 - PubMed

Publication types

MeSH terms